158 related articles for article (PubMed ID: 12752223)
21. Cellular proliferative and telomerase activity in canine mammary gland tumors.
Funakoshi Y; Nakayama H; Uetsuka K; Nishimura R; Sasaki N; Doi K
Vet Pathol; 2000 Mar; 37(2):177-83. PubMed ID: 10714647
[TBL] [Abstract][Full Text] [Related]
22. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
[TBL] [Abstract][Full Text] [Related]
23. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
24. CD117 expression influences proliferation but not survival in canine mammary tumours.
Brunetti B; Beha G; Benazzi C; Bondin V; De Tolla L; Sarli G
J Comp Pathol; 2014; 151(2-3):202-6. PubMed ID: 25027114
[TBL] [Abstract][Full Text] [Related]
25. Immunocytochemical evaluation of proliferative activity in human brain tumours.
Girino M; Riccardi A; Danova M; Gaetani P; Butti G; Giordano M; Cuomo A
Anal Cell Pathol; 1990 Sep; 2(5):269-75. PubMed ID: 2275874
[TBL] [Abstract][Full Text] [Related]
26. Expression of connexins 26 and 43 in canine hyperplastic and neoplastic mammary glands.
Torres LN; Matera JM; Vasconcellos CH; Avanzo JL; Hernandez-Blazquez FJ; Dagli ML
Vet Pathol; 2005 Sep; 42(5):633-41. PubMed ID: 16145209
[TBL] [Abstract][Full Text] [Related]
27. Expression of Ki-67, PCNA, and p27kip1 in canine pituitary corticotroph adenomas.
van Rijn SJ; Grinwis GC; Penning LC; Meij BP
Domest Anim Endocrinol; 2010 May; 38(4):244-52. PubMed ID: 20022446
[TBL] [Abstract][Full Text] [Related]
28. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
[TBL] [Abstract][Full Text] [Related]
29. Measurement of cell proliferation in gastric carcinoma: comparative analysis of Ki-67 and proliferative cell nuclear antigen (PCNA).
Rosa JC; Mendes R; Filipe MI; Morris RW
Histochem J; 1992 Feb; 24(2):93-101. PubMed ID: 1349600
[TBL] [Abstract][Full Text] [Related]
30. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
31. Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours.
Kordek R; Biernat W; Alwasiak J; Liberski PP
Acta Neurochir (Wien); 1996; 138(5):509-12; discussion 513. PubMed ID: 8800324
[TBL] [Abstract][Full Text] [Related]
32. Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas.
Nowak M; Madej JA; Podhorska-Okolow M; Dziegiel P
In Vivo; 2008; 22(4):463-9. PubMed ID: 18712173
[TBL] [Abstract][Full Text] [Related]
33. Comparison of proliferating cell nuclear antigen (PCNA) staining and BrdUrd-labelling index under different proliferative conditions in vitro by flow cytometry.
Lohr F; Wenz F; Haas S; Flentje M
Cell Prolif; 1995 Feb; 28(2):93-104. PubMed ID: 7893842
[TBL] [Abstract][Full Text] [Related]
34. Cell kinetics in mandibular ameloblastic fibro-odontoma evaluated by bromodeoxyuridine and proliferating cell nuclear antigen immunohistochemistry: case report.
Sekine J; Kitamura A; Ueno K; Sano K; Inokuchi T; Takahashi H; Okabe H
Br J Oral Maxillofac Surg; 1996 Oct; 34(5):450-3. PubMed ID: 8909741
[TBL] [Abstract][Full Text] [Related]
35. Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma.
Kang SM; Kim WH; Kim CW; Kim YI
J Korean Med Sci; 1994 Feb; 9(1):16-20. PubMed ID: 7915118
[TBL] [Abstract][Full Text] [Related]
36. Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention.
Risio M
J Cell Biochem Suppl; 1994; 19():61-7. PubMed ID: 7823607
[TBL] [Abstract][Full Text] [Related]
37. Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling.
Lee KS; Yang WI
Yonsei Med J; 1992 Sep; 33(3):265-71. PubMed ID: 1363339
[TBL] [Abstract][Full Text] [Related]
38. Expression of E-cadherin, beta-catenin and Ki-67 antigen and their reciprocal relationships in mammary adenocarcinomas in bitches.
Nowak M; Madej JA; Dziegiel P
Folia Histochem Cytobiol; 2007; 45(3):233-8. PubMed ID: 17951173
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of dog TERT in canine testicular tumours in relation to PCNA, ki67 and p53 expression.
Papaioannou N; Psalla D; Zavlaris M; Loukopoulos P; Tziris N; Vlemmas I
Vet Res Commun; 2009 Dec; 33(8):905-19. PubMed ID: 19655265
[TBL] [Abstract][Full Text] [Related]
40. Proliferating cell nuclear antigen expression in central nervous system neoplasms.
Allegranza A; Girlando S; Arrigoni GL; Veronese S; Mauri FA; Gambacorta M; Pollo B; Dalla Palma P; Barbareschi M
Virchows Arch A Pathol Anat Histopathol; 1991; 419(5):417-23. PubMed ID: 1721471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
